Professor, Medicine - Immunology and Rheumatology, Stanford University Medical Center
Rheumatology
Dr. Mark C. Genovese, MD
|
|
Give Review
Mark Genovese is an expert in the field of Rheumatology. He went to Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is one of the top medical schools in the US. Johns Hopkins University School of Medicine is ranked 3/29 in Research/PrimaryCare. He over the years received 4 awards: "CMS Meaningful Use Stage 1 Certification", "Fellow (FACP)", "Fellow (FACR)" and "Fellow". Mark Genovese is a published MD. He has 64 papers published. The most current publication "Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis." Mark Genovese is registered with Medicare.
Publications
- Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial.
- Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis.
- Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis.
- Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid Arthritis.
- Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid Arthritis.
- Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirhe...
- Sarilumab plus methotrexate in patients with active rheumatoid Arthritis and inadequate response to methotrexate: Results of a phase III study.
- Apremilast in patients with active rheumatoid Arthritis: A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
- Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid Arthritis who have had an inadequate response to methotrexate.
- Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid Arthritis patients with an inadequate response to methotrexate: Results from a phase I...
- A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis...
- Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic Arthritis.
- Phase 2 randomized study of subcutaneous ixekizumab, an Anti-IL-17 monoclonal antibody, in biologic-naïve or TNF-IR patients with rheumatoid Arthritis.
- One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study.
- Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis: Longterm Data from the ACQUIRE Trial.
- Effect of golimumab on carotid atherosclerotic Disease measures and cardiovascular events in inflammatory arthritides.
- Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 2 Years of the GO-FORWARD Study Extension.
- A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid Arthritis and an inadequate response to methotrexate.
- Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study.
- Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure.
- Tocilizumab as monotherapy or in combination with nonbiologic Disease-modifying antirheumatic drugs: Twenty-four-week results of an open-label, clinical practice study.
- Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of P...
- Tabalumab in patients with rheumatoid Arthritis with an inadequate response to methotrexate and naive to biologic therapy.
- Novel small molecule therapeutics in rheumatoid Arthritis.
- Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid Arthritis with an inadequate response to TNF inhibitors.
- Effects of sclerostin antibody on healing of a non-critical size femoral bone defect.
- Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibi...
- Efficacy and safety of secukinumab in patients with rheumatoid Arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.
- Effect of Golimumab on Patient-reported Outcomes in Rheumatoid Arthritis: Results from the GO-FORWARD Study.
- Reply to letter to the editor regarding "The effect of golimumab on radiographic progression in rheumatoid Arthritis:
- Phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid Arthritis wi...
- Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid Arthritis.
- IL-17 receptor and its functional significance in psoriatic Arthritis.
- Assessment by MRI of inflammation and damage in rheumatoid Arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial.
- The effects of golimumab on radiographic progression in rheumatoid Arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and gol...
- Abatacept in the treatment of patients with psoriatic Arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.
- An oral Syk kinase inhibitor in the treatment of rheumatoid Arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid ...
- An oral syk kinase inhibitor in the treatment of rheumatoid Arthritis: A 3 month randomized placebo controlled phase 2 study in patients with active RA who had failed ...
- Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and long-standing rheumatoid Arthritis.
- An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid Arthritis.
- Safety of biological therapies following rituximab treatment in rheumatoid Arthritis patients.
- Inhibition of p38: has the fat lady sung?
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid Arthritis with inadequate response to disease-modifying antirheumatic drugs: ...
- A pilot trial of rituximab in the treatment of patients with Dermatomyositis.
- Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune Arthritis.
- Effect of etanercept on fatigue in patients with recent or established rheumatoid Arthritis.
- Computer-assisted pattern recognition of autoantibody results.
- Management of co-morbidities and general medical conditions in patients with rheumatoid Arthritis.
- Abatacept for rheumatoid Arthritis refractory to tumor necrosis factor alpha inhibition.
- Antigen microarray profiling of autoantibodies in rheumatoid Arthritis.
- Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus.
- Biologic therapies in clinical development for the treatment of rheumatoid Arthritis.
- Temporal effects of a COX-2-selective NSAID on bone ingrowth.
- Effects of prasterone on Disease activity and symptoms in women with active systemic lupus erythematosus.
- Associations between rheumatoid Arthritis and malignancy.
- Treatment of rheumatoid Arthritis with etanercept.
- A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid Arthritis: a pilot study [ISRCTN03626626].
- Rheumatic Syndromes associated with malignancy.
- Concomitant leflunomide therapy in patients with active rheumatoid Arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial.
- Etanercept versus methotrexate in patients with early rheumatoid Arthritis: two-year radiographic and clinical outcomes.
- Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis.
- Autoantigen microarrays for multiplex characterization of autoantibody Responses.
- Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes.
Schools
Johns Hopkins University School Of Medicine
Stanford University
Procedures Preformed
- Joint Drainage
- Steroid Injection
- Viscosupplementation With Hyaluronate
Conditions Treated
- Adhesive Capsulitis
- Ankylosing Spondylitis
- Antiphospholipid Syndrome (APS)
- Arthritis
- View All
Doctors Specialties
- Rheumatology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- CaliforniaCare HMO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Select Plus HMO
- Select PPO
- Access Plus Savenet
- Basic Exclusive PPO for Small Business
- Basic PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- First Health (Coventry Health Care) PPO
- GEHA
- Covered California - Bronze PPO
- Health Net PPO
- Individual and Family PPO
- Medicaid
- Medicare MCR
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- Heritage Signature
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- PacifiCare HMO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACP)
- Fellow (FACR)
- Fellow
Education
-
Stanford University -
Johns Hopkins University School of Medicine
Hospital
-
VA Palo Alto Health Care System -
Stanford Health Care
Drug Facts
| NPI NUMBER | 1487711875 | |
| NPPES Provider LastName | GENOVESE | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 943041811 | |
| NPPES Provider State | CA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 789.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1487711875 |
| Last Name Of The Provider | GENOVESE |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
|
Dr. David Fischer, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ariella S. Kelman, MD |
|
|
Dr. James F. Fries, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stuart H. Koretz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Veronika Sharp, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeremy Sokolove, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey D. Urman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anne-Marie Duliege, MD |
|
|
Dr. Rebecca S. Kunder, MD |
|
|
Dr. Halsted R. Holman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laura F. Su, MD |